NMRD (Nemaura Medical) EBITDA Margin %: 0.00% (As of Dec. 2023)

What is Nemaura Medical EBITDA Margin %?

Nemaura Medical NMRD EBITDA Margin % is 0.00% as of Dec. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nemaura Medical's EBITDA for the three months ended in Dec. 2023 was $-0.16 Mil. Nemaura Medical's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Nemaura Medical's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Nemaura Medical (OTCPK:NMRD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nemaura Medical EBITDA Margin % Related Terms

Nemaura Medical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Nemaura Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nemaura Medical EBITDA Margin % Chart

Nemaura Medical Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-1,456.55

-9,463.64

Nemaura Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial															-17,900.00	0.00	0.00	0.00	0.00

NMRD vs THMO, MOTS, ABT: EBITDA Margin % Comparison

For the Medical Devices subindustry, Nemaura Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nemaura Medical EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nemaura Medical's EBITDA Margin % falls into.

Save Embed

Nemaura Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nemaura Medical's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-7.287	/	0.077
	=	-9,463.64 %

Nemaura Medical's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.155	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Nemaura Medical (NMRD) has a EBITDA Margin % of 0.00% as of Dec. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nemaura Medical and its competitors.

Is Nemaura Medical's EBITDA Margin % too high?

Nemaura Medical's current EBITDA Margin % is 0.00%.

How does Nemaura Medical's EBITDA Margin % compare to THMO and MOTS?

Nemaura Medical's EBITDA Margin % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Medical Devices & Instruments company?

The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nemaura Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nemaura Medical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nemaura Medical stock overvalued right now?

Nemaura Medical (NMRD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Nemaura Medical (NMRD), the current EBITDA Margin % is 0.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nemaura Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies THMO MOTS ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH STE XSWX:SOON PODD SHSE:688271 ASX:COH GMED LSE:SN.BIO

Address 57 West 57th Street, New York, NY, USA, 10019

Website https://www.nemauramedical.com

Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.